HRP20100218T1 - Egzo- i dijastereoselektivna sinteza analoga himbacina - Google Patents
Egzo- i dijastereoselektivna sinteza analoga himbacina Download PDFInfo
- Publication number
- HRP20100218T1 HRP20100218T1 HR20100218T HRP20100218T HRP20100218T1 HR P20100218 T1 HRP20100218 T1 HR P20100218T1 HR 20100218 T HR20100218 T HR 20100218T HR P20100218 T HRP20100218 T HR P20100218T HR P20100218 T1 HRP20100218 T1 HR P20100218T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- group
- image
- chain
- alkyl
- Prior art date
Links
- FMPNFDSPHNUFOS-LPJDIUFZSA-N himbacine Chemical class C(/[C@@H]1[C@H]2CCCC[C@@H]2C[C@@H]2C(=O)O[C@H]([C@H]12)C)=C\[C@H]1CCC[C@H](C)N1C FMPNFDSPHNUFOS-LPJDIUFZSA-N 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 82
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 52
- 125000000217 alkyl group Chemical group 0.000 claims abstract 38
- 125000003118 aryl group Chemical group 0.000 claims abstract 35
- 125000001931 aliphatic group Chemical group 0.000 claims abstract 31
- 239000000203 mixture Substances 0.000 claims abstract 28
- 239000002904 solvent Substances 0.000 claims abstract 22
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 21
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 21
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 21
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 21
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 19
- 125000004429 atom Chemical group 0.000 claims abstract 19
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 11
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract 10
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims abstract 10
- 125000004122 cyclic group Chemical group 0.000 claims abstract 10
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 10
- 125000003367 polycyclic group Chemical group 0.000 claims abstract 10
- 125000006413 ring segment Chemical group 0.000 claims abstract 10
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 10
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 8
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 claims abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 7
- 238000007363 ring formation reaction Methods 0.000 claims abstract 7
- 150000000644 6-membered heterocyclic compounds Chemical class 0.000 claims abstract 6
- 229940125782 compound 2 Drugs 0.000 claims abstract 6
- 125000005842 heteroatom Chemical group 0.000 claims abstract 6
- 229940125904 compound 1 Drugs 0.000 claims abstract 5
- -1 nitro- Chemical class 0.000 claims abstract 4
- 238000001556 precipitation Methods 0.000 claims abstract 3
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 claims abstract 2
- 229940127204 compound 29 Drugs 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 55
- 238000006243 chemical reaction Methods 0.000 claims 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 18
- 229940125773 compound 10 Drugs 0.000 claims 18
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims 18
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims 10
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims 10
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims 10
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 10
- 229940125758 compound 15 Drugs 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 7
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 claims 7
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims 6
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 6
- 239000003054 catalyst Substances 0.000 claims 6
- 229940126543 compound 14 Drugs 0.000 claims 6
- 229940126086 compound 21 Drugs 0.000 claims 6
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims 5
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 claims 5
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims 5
- 229940126142 compound 16 Drugs 0.000 claims 5
- 229940126208 compound 22 Drugs 0.000 claims 5
- 229940126214 compound 3 Drugs 0.000 claims 5
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims 5
- 239000008096 xylene Substances 0.000 claims 5
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims 4
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 claims 4
- 229940126657 Compound 17 Drugs 0.000 claims 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 229940125833 compound 23 Drugs 0.000 claims 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 3
- 229910004879 Na2S2O5 Inorganic materials 0.000 claims 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 3
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 150000003335 secondary amines Chemical class 0.000 claims 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 3
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 claims 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims 2
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 claims 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 claims 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 claims 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 2
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 2
- 239000003377 acid catalyst Substances 0.000 claims 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims 2
- 229940125797 compound 12 Drugs 0.000 claims 2
- 229940125810 compound 20 Drugs 0.000 claims 2
- 229940125961 compound 24 Drugs 0.000 claims 2
- 229940125846 compound 25 Drugs 0.000 claims 2
- 229940125851 compound 27 Drugs 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 2
- 150000007529 inorganic bases Chemical class 0.000 claims 2
- 150000002576 ketones Chemical class 0.000 claims 2
- 229910052808 lithium carbonate Inorganic materials 0.000 claims 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 229910000510 noble metal Inorganic materials 0.000 claims 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 2
- 235000015320 potassium carbonate Nutrition 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 2
- 235000017550 sodium carbonate Nutrition 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims 1
- 239000003849 aromatic solvent Substances 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 230000002051 biphasic effect Effects 0.000 claims 1
- 229910000024 caesium carbonate Inorganic materials 0.000 claims 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims 1
- 239000000920 calcium hydroxide Substances 0.000 claims 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims 1
- 235000011116 calcium hydroxide Nutrition 0.000 claims 1
- 125000005265 dialkylamine group Chemical group 0.000 claims 1
- VYSRWEZGKYVHQG-UHFFFAOYSA-N ethyl carboniodidate Chemical compound CCOC(I)=O VYSRWEZGKYVHQG-UHFFFAOYSA-N 0.000 claims 1
- XCPXPFNKTCFWTA-UHFFFAOYSA-N ethyl carbonobromidate Chemical compound CCOC(Br)=O XCPXPFNKTCFWTA-UHFFFAOYSA-N 0.000 claims 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 229910000032 lithium hydrogen carbonate Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 125000002524 organometallic group Chemical group 0.000 claims 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 1
- 239000011736 potassium bicarbonate Substances 0.000 claims 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims 1
- 235000015497 potassium bicarbonate Nutrition 0.000 claims 1
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 claims 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims 1
- 235000010263 potassium metabisulphite Nutrition 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 1
- 230000003068 static effect Effects 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
- C07C201/10—Preparation of nitro compounds by substitution of functional groups by nitro groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
- C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/44—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/55—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/07—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton
- C07C309/08—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton containing hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/606—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom having only or additionally carbon-to-carbon triple bonds as unsaturation in the carboxylic acid moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Postupak dobivanja Spoja 1:naznačen time što se navedeni postupak sastoji u koracima: (a) ciklizacije Spoja 2 u prvom otapalu, na povišenoj temperaturigdje svakog od R5 i R6 se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne, heterocikličke i heteroarilne skupine, ili R5 i R6, zajedno s dušikom na kojeg su vezani, tvore 3- do 6-eročlani heterociklički spoj s 1-4 heteroatoma, kako bi se dobilo prvu smjesu exo-izomeragdje navedeni izomeri imaju trans-[5,6]-vezu u prstenu; i endo-izomera: (b) epimerizacije navedene trans-[5,6]-veze u prstenu u Spoju 29 obradom navedene prve smjese prvom bazom kako bi se dobilo drugu smjesu, koju čini nitro-α izomer s cis-[5,6]-vezom u prstenu i nitro-? izomer s cis-[5,6]-vezom u prstenu Spoja 30:i (c) obrade navedene druge smjese drugim otapalom, koje uzrokuje taloženje navedenog α-izomera Spoja 30 kako bi se dobilo Spoj 1,gdje: "alkil" znači alifatska ugljikovodična skupina koja može biti nerazgranata ili razgranata i sadrži 1 do 24 atoma ugljika u lancu; "alkenil" znači alifatska ugljikovodična skupina s nerazgranatim ili razgranatim lancem ugljika comprising jedan ili više dvostrukih veza u lancu, koje mogu biti konjugirane ili nekonjugirane, a osobito sadrži 2 do 15 atoma ugljika u lancu; "alkinil" znači alifatska ugljikovodična skupina koja sadrži najmanje jednu trostruku vezu ugljik-ugljik i može biti nerazgranata ili razgranata i sadrži 2 do 15 atoma ugljika u lancu; "alkoksi" znači alkil-O- skupina, u kojoj alkilna skupina je kao što je definirano gore, a osobito sadrži 1 do 12 atoma ugljika; "cikloalkil" znači nesupstituirani ili supstituirani, zasićeni, stabilni, nearomatski, kemijski izvediv karbociklički prsten s, po mogućnosti, 3 do 15 atoma ugljika; "heteroaril" znači monociklički ili policiklički aromatski prstenasti sustav s 5 do 14 atoma u prstenu, gdje jedan ili više atoma u prstenastom sustavu je/su atomi koji nisu ugljik. Patent sadrži još 73 patentna zahtjeva.
Claims (74)
1. Postupak dobivanja Spoja 1:
[image]
naznačen time što se navedeni postupak sastoji u koracima:
(a) ciklizacije Spoja 2 u prvom otapalu, na povišenoj temperaturi
[image]
gdje svakog od R5 i R6 se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne, heterocikličke i heteroarilne skupine, ili R5 i R6, zajedno s dušikom na kojeg su vezani, tvore 3- do 6-eročlani heterociklički spoj s 1-4 heteroatoma,
kako bi se dobilo prvu smjesu exo-izomera
[image]
gdje navedeni izomeri imaju trans-[5,6]-vezu u prstenu;
i endo-izomera:
(b) epimerizacije navedene trans-[5,6]-veze u prstenu u Spoju 29 obradom navedene prve smjese prvom bazom kako bi se dobilo drugu smjesu, koju čini nitro-α izomer s cis-[5,6]-vezom u prstenu i nitro-β izomer s cis-[5,6]-vezom u prstenu Spoja 30:
[image]
i
(c) obrade navedene druge smjese drugim otapalom, koje uzrokuje taloženje navedenog α-izomera Spoja 30 kako bi se dobilo Spoj 1,
gdje:
"alkil" znači alifatska ugljikovodična skupina koja može biti nerazgranata ili razgranata i sadrži 1 do 24 atoma ugljika u lancu;
"alkenil" znači alifatska ugljikovodična skupina s nerazgranatim ili razgranatim lancem ugljika comprising jedan ili više dvostrukih veza u lancu, koje mogu biti konjugirane ili nekonjugirane, a osobito sadrži 2 do 15 atoma ugljika u lancu;
"alkinil" znači alifatska ugljikovodična skupina koja sadrži najmanje jednu trostruku vezu ugljik-ugljik i može biti nerazgranata ili razgranata i sadrži 2 do 15 atoma ugljika u lancu;
"alkoksi" znači alkil-O- skupina, u kojoj alkilna skupina je kao što je definirano gore, a osobito sadrži 1 do 12 atoma ugljika;
"cikloalkil" znači nesupstituirani ili supstituirani, zasićeni, stabilni, nearomatski, kemijski izvediv karbociklički prsten s, po mogućnosti, 3 do 15 atoma ugljika;
"heteroaril" znači monociklički ili policiklički aromatski prstenasti sustav s 5 do 14 atoma u prstenu, gdje jedan ili više atoma u prstenastom sustavu je/su atomi koji nisu ugljik.
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što se dodatno sastoji u koraku obrade navedene druge smjese drugom bazom, što uzrokuje dinamičko razdvajanje navedene druge smjese, u kojoj navedeni β-izomer Spoja 30 se prevodi u α-izomer Spoja 30, a α-izomer Spoja 30 se istaloži kako bi se dobilo Spoj 1.
3. Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeno prvo otapalo se bira iz skupine koju čine ksilen, N-metilpirolidinon, dimetil-sulfoksid, difenil-eter, dimetilacetamid, te smjese 2 ili više njih.
4. Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedena temperatura je između otprilike 70 i otprilike 190 °C.
5. Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedena temperatura je između otprilike 80 i otprilike 170 °C.
6. Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedena temperatura je između otprilike 100 i otprilike 160 °C.
7. Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedena temperatura je između otprilike 120 i otprilike 150 °C.
8. Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedenu prvu bazu se bira iz skupine koju čine trietilamin, 1,5-diazabiciklo[4.3.0]non-5-en, 1,4-diazabiciklo[2.2.2]oktan i 1,8-diazabiciklo[5.4.0]undec-7-en, te smjese 2 ili više njih.
9. Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeno drugo otapalo se bira iz skupine koju čine eteri, ketoni, esteri, amidi, sulfoksidi, alifatski ugljikovodici, aromatski ugljikovodici, te smjese 2 ili više njih.
10. Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeno drugo otapalo se bira iz skupine koju čine ksilen, N-metilpirolidinon, dimetilacetamid, DMSO, te smjese 2 ili više njih.
11. Postupak u skladu s patentnim zahtjevom 2, naznačen time što navedenu drugu bazu se bira iz skupine koju čine trietilamin, 1,5-diazabiciklo[4.3.0]non-5-en, 1,4-diazabiciklo[2.2.2]oktan i 1,8-diazabiciklo[5.4.0]undec-7-en, te smjese 2 ili više njih.
12. Postupak dobivanja Spoja 2:
[image]
gdje svakog od R5 i R6 se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne, heterocikličke i heteroarilne skupine, ili R5 i R6, zajedno s dušikom na kojeg su vezani, tvore 3- do 6-eročlani heterociklički spoj s 1 -4 heteroatoma, naznačen time što navedeni postupak se sastoji u:
(a) prevođenju (R)-butinola u Spoj 3:
[image]
(b) redukciji Spoja 3 kako bi se dobilo Spoj 4:
[image]
i
(c) reakciji Spoja 4 sa Spojem 6:
[image]
kako bi se dobilo Spoj 2,
gdje:
"alkil" znači alifatska ugljikovodična skupina koja može biti nerazgranata ili razgranata i sadrži 1 do 24 atoma ugljika u lancu;
"alkenil" znači alifatska ugljikovodična skupina s nerazgranatim ili razgranatim lancem ugljika comprising jedan ili više dvostrukih veza u lancu, koje mogu biti konjugirane ili nekonjugirane, a osobito sadrži 2 do 15 atoma ugljika u lancu;
"alkinil" znači alifatska ugljikovodična skupina koja sadrži najmanje jednu trostruku vezu ugljik-ugljik i može biti nerazgranata ili razgranata i sadrži 2 do 15 atoma ugljika u lancu;
"alkoksi" znači alkil-O- skupina, u kojoj alkilna skupina je kao što je definirano gore, a osobito sadrži 1 do 12 atoma ugljika;
"cikloalkil" znači nesupstituirani ili supstituirani, zasićeni, stabilni, nearomatski, kemijski izvediv karbociklički prsten s, po mogućnosti, 3 do 15 atoma ugljika;
"heteroaril" znači monociklički ili policiklički aromatski prstenasti sustav s 5 do 14 atoma u prstenu, gdje jedan ili više atoma u prstenastom sustavu je/su atomi koji nisu ugljik.
13. Postupak u skladu s patentnim zahtjevom 12, naznačen time što Spoj 3 se dobiva postupkom kojeg se bira iz skupine koju čine:
(a)
[image]
i
(b)
[image]
gdje:
P je zaštitna skupina;
X je izlazna skupina, koju se bira iz skupine koju čine Cl, Br, I i heterociklički prsteni;
L se bira iz skupine koju čine PR'3 i NR''3,
gdje R' se bira iz skupine koju čine alkil, aril, alkilaril, a R'' se bira iz skupine koju čine alkil, aril, i alkilaril;
Y se bira iz skupine koju čine Cl, Br, I i R'''COO, gdje R''' se bira iz skupine koju čine alkil, aril, alkilaril i arilalkil; i
n je između 0 i 4.
14. Postupak u skladu s patentnim zahtjevom 12, naznačen time što Spoj 6 se dobiva postupkom koji se sastoji u:
(a) reakciji akroleina s CH3NO2, u prisutnosti anorganske baze, u C1-C8 alkoholu, kako bi se dobilo sirovi Spoj 8:
[image]
(b) reakciji sirovog Spoja 8 s metalnim bisulfitom kako bi se dobilo Spoj 9:
[image]
(c) obradi Spoja 9 nižim alkilkarbonilnim spojem i karbonatnom bazom u dvofaznom sustavu otapala kako bi se dobilo pročišćeni Spoj 8;
(d) reakciji navedenog pročišćenog Spoja 8 sekundarnim aminom i karboksilnom kiselinom u prvom otapalu kako bi se dobilo Spoj 10:
[image]
i
(e) prevođenju Spoja 10 u Spoj 6;
gdje "niži alkil" znači alkilne skupine s 1 do 6 atoma ugljika u lancu.
15. Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedenu anorgansku bazu se bira iz skupine koju čine LiOH, KOH, NaOH, Ca(OH)2, Li2CO3, Na2CO3, K2CO3 i Cs2CO3.
16. Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni alkohol se bira iz skupine koju čine metanol, etanol, propanol, izopropanol, butanol, sec-butanol, t-butanol, pentanol, oktanol, te smjese 2 ili više njih.
17. Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni niži alkilkarbonilni spoj se bira iz skupine koju čine acetaldehid, aceton, glioksilna kiselina i giloksilat.
18. Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni metalni bisulfit se bira iz skupine koju čine NaHSO3, KHSO3, Na2S2O5, i K2S2O5.
19. Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedenu karbonatnu bazu se bira iz skupine koju čine LiHCO3, NaHCO3, KHCO3, Li2CO3, Na2CO3 i K2CO3.
20. Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni dvofazni sustav otapala se sastoji od vode i otapala koje se ne miješa s vodom.
21. Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni sekundarni amin se bira iz skupine koju čine piperidin, pirolidin, piperazin, dialkilamini i diarilalkilamini.
22. Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni sekundarni amin je pirolidin.
23. Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedenu karboksilnu kiselinu se bira iz skupine koju čine alifatske i aromatske karboksilne kiseline.
24. Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedena karboksilna kiselina je benzojeva kiselina.
25. Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeno prvo otapalo se bira iz skupine koju čine CH2Cl2, klorbenzen, t-butilmetil-eter i toluen.
26. Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni korak prevođenja Spoja 10 u Spoj 6 se sastoji u koracima:
(a) reakcije Spoja 10 s Ph3P=CHCOOR8 kako bi se dobilo Spoj 6A:
[image]
i
(b) hidrolize Spoja 6A u Spoj 6 obradom Spoja 6A baznim katalizatorom ili kiselinskim katalizatorom:
[image]
gdje R8 je C1 do C10 alkil ili arilalkil.
27. Postupak u skladu s patentnim zahtjevom 26, naznačen time što navedeni bazni katalizator se bira iz skupine koju čine alkalne hidroksidne, karbonatne i fosfatne baze.
28. Postupak u skladu s patentnim zahtjevom 26, naznačen time što navedeni kiselinski katalizator se bira iz skupine koju čine mineralne i organske kiseline.
29. Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni korak prevođenja Spoja 10 u Spoj 6 se sastoji u reakciji Spoja 10 s malonskom kiselinom u drugom otapalu.
30. Postupak u skladu s patentnim zahtjevom 29, naznačen time što navedeno drugo otapalo se bira iz skupine koju čine halogenirana otapala, aromatska otapala i otapala koja sadrže dušik.
31. Postupak u skladu s patentnim zahtjevom 29, naznačen time što navedeno drugo otapalo se bira iz skupine koju čine piridin i toluen.
32. Postupak u skladu s patentnim zahtjevom 29, naznačen time što se dodatno sastoji u upotrebi katalizatora na bazi dušika kako bi se ubrzalo reakciju, gdje navedeni katalizator na bazi dušika se bira iz skupine koju čine piperidin, pirolidin, piperazin, piridin i trietilamin.
33. Postupak dobivanja Spoja 11:
[image]
naznačen time što se sastoji u koracima:
(a) redukcije Spoja 1
[image]
u Spoj 12, uz upotrebu katalizatora na bazi plemenitog metala:
[image]
(b) reakcije Spoja 12 s alkil-halogenformijatom kako bi se dobilo Spoj 13:
[image]
(c) reakcije Spoja 13 s bazom kako bi se dobilo Spoj 14:
[image]
(d) prevođenju Spoja 14 u Spoj 15:
[image]
i
(e) reakciji Spoja 15 sa Spojem 16 kako bi se dobilo Spoj 11:
[image]
34. Postupak u skladu s patentnim zahtjevom 33, naznačen time što navedeni katalizator na bazi plemenitog metala se bira iz skupine koju čine paladij na ugljiku, platina na ugljiku i rodij na ugljiku, ili njihova smjesa.
35. Postupak u skladu s patentnim zahtjevom 33, naznačen time što navedeni alkil-halogenformijat se bira iz skupine koju čine etil-klorformijat, etil-bromformijat i etil-jodformijat.
36. Postupak dobivanja Spoja 17:
[image]
naznačen time što se navedeni postupak sastoji u koracima:
(a) ciklizacije Spoja 18 u prvom otapalu, na povišenoj temperaturi
[image]
gdje R7 se bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne i heteroarilne skupine
kako bi se dobilo prvu smjesu, koju čine α- i β-exo-izomer Spoja 17A:
[image]
i α- i β-endo-izomer Spoja 17B:
[image]
gdje navedeni izomeri Spoja 17A imaju trans-[5,6]-vezu u prstenu;
(b) epimerizacije navedene trans-[5,6]-veze u prstenu Spoja 17A obradom navedene prve smjese prvom bazom kako bi se dobilo drugu smjesu, koju čine nitro-α izomer s cis-[5,6]-vezom u prstenu i nitro-β izomer s cis-[5,6]-vezom u prstenu svakog od Spoja 17C i Spoja 17B:
[image]
i
(c) obrade navedene druge smjese drugim otapalom, što uzrokuje taloženje navedenog α-izomera Spoja 17C kako bi se dobilo Spoj 17,
gdje:
"alkil" znači alifatska ugljikovodična skupina koja može biti nerazgranata ili razgranata i sadrži 1 do 24 atoma ugljika u lancu;
"alkenil" znači alifatska ugljikovodična skupina s nerazgranatim ili razgranatim lancem ugljika comprising jedan ili više dvostrukih veza u lancu, koje mogu biti konjugirane ili nekonjugirane, a osobito sadrži 2 do 15 atoma ugljika u lancu;
"alkinil" znači alifatska ugljikovodična skupina koja sadrži najmanje jednu trostruku vezu ugljik-ugljik i može biti nerazgranata ili razgranata i sadrži 2 do 15 atoma ugljika u lancu;
"alkoksi" znači alkil-O- skupina, u kojoj alkilna skupina je kao što je definirano gore, a osobito sadrži 1 do 12 atoma ugljika;
"cikloalkil" znači nesupstituirani ili supstituirani, zasićeni, stabilni, nearomatski, kemijski izvediv karbociklički prsten s, po mogućnosti, 3 do 15 atoma ugljika;
"heteroaril" znači monociklički ili policiklički aromatski prstenasti sustav s 5 do 14 atoma u prstenu, gdje jedan ili više atoma u prstenastom sustavu je/su atomi koji nisu ugljik.
37. Postupak u skladu s patentnim zahtjevom 36, naznačen time što se dodatno sastoji u koraku obrade navedene druge smjese drugom bazom, što uzrokuje dinamičko razdvajanje navedene druge smjese, u kojoj navedeni β-izomer Spoja 17C se prevodi u α-izomer Spoja 17C, te se α-izomer Spoja 17C istaloži kako bi se dobilo Spoj 17.
38. Postupak u skladu s patentnim zahtjevom 36, naznačen time što navedeno prvo otapalo se bira iz skupine koju čine ksilen, N-metilpirolidinon, dimetil-sulfoksid, difenil-eter i dimetilacetamid, te smjese 2 ili više njih.
39. Postupak u skladu s patentnim zahtjevom 36, naznačen time što navedena temperatura je između otprilike 70 i otprilike 190 °C.
40. Postupak u skladu s patentnim zahtjevom 36, naznačen time što navedena temperatura je između otprilike 80 i otprilike 170 °C.
41. Postupak u skladu s patentnim zahtjevom 36, naznačen time što navedena temperatura je između otprilike 100 i otprilike 160 °C.
42. Postupak u skladu s patentnim zahtjevom 36, naznačen time što navedena temperatura je između otprilike 120 i otprilike 150 °C.
43. Postupak u skladu s patentnim zahtjevom 36, wherein saidprvu bazu se bira iz skupine koju čine trietilamin; 1,5-diazabiciklo[4.3.0]non-5-en; 1,4-diazabiciklo[2.2.2]oktan; i 1,8-diazabiciklo[5.4.0]undec-7-en; te smjese 2 ili više njih.
44. Postupak u skladu s patentnim zahtjevom 36, naznačen time što navedeno drugo otapalo se bira iz skupine koju čine alkohols, eteri, ketoni, esteri, ksilen i N-metilpirolidinon, te smjese 2 ili više njih.
45. Postupak u skladu s patentnim zahtjevom 36, naznačen time što navedeno drugo otapalo se bira iz skupine koju čine metanol, etanol, propanoli i butanoli, ksilen, N-metilpirolidinon, te smjese 2 ili više njih.
46. Postupak u skladu s patentnim zahtjevom 37, naznačen time što navedenu drugu bazu se bira iz skupine koju čine trietilamin; 1,5-diazabiciklo[4.3.0]non-5-en; 1,4-diazabiciklo[2.2.2]oktan; 1,8-diazabiciklo[5.4.0]undec-7-en; i smjese 2 ili više njih.
47. Postupak dobivanja Spoja 18:
[image]
gdje R7 se bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne i heteroarilne skupine,
naznačen time što se navedeni postupak sastoji u koracima:
(a) prevođenja (R)-butinola u Spoj 28:
[image]
gdje R7 se bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne i heteroarilne skupine;
(b) reakcije Spoja 28 sa Spojem 6:
[image]
kako bi se dobilo Spoj 19:
[image]
i
(c) redukcije Spoja 19 kako bi se dobilo Spoj 18:
[image]
gdje:
"alkil" znači alifatska ugljikovodična skupina koja može biti nerazgranata ili razgranata i sadrži 1 do 24 atoma ugljika u lancu;
"alkenil" znači alifatska ugljikovodična skupina s nerazgranatim ili razgranatim lancem ugljika comprising jedan ili više dvostrukih veza u lancu, koje mogu biti konjugirane ili nekonjugirane, a osobito sadrži 2 do 15 atoma ugljika u lancu;
"alkinil" znači alifatska ugljikovodična skupina koja sadrži najmanje jednu trostruku vezu ugljik-ugljik i može biti nerazgranata ili razgranata i sadrži 2 do 15 atoma ugljika u lancu;
"alkoksi" znači alkil-O- skupina, u kojoj alkilna skupina je kao što je definirano gore, a osobito sadrži 1 do 12 atoma ugljika;
"cikloalkil" znači nesupstituirani ili supstituirani, zasićeni, stabilni, nearomatski, kemijski izvediv karbociklički prsten s, po mogućnosti, 3 do 15 atoma ugljika;
"heteroaril" znači monociklički ili policiklički aromatski prstenasti sustav s 5 do 14 atoma u prstenu, gdje jedan ili više atoma u prstenastom sustavu je/su atomi koji nisu ugljik.
48. Postupak u skladu s patentnim zahtjevom 47, naznačen time što Spoj 6 se dobiva postupkom koji se sastoji u:
(a) reakciji akroleina s CH3NO2 kako bi se dobilo Spoj 8:
[image]
(b) reakciji Spoja 8 s Na2S2O5 kako bi se dobilo Spoj 9:
[image]
(c) reakciji Spoja 9 s kiselinom kako bi se dobilo Spoj 10:
[image]
i
(d) prevođenju Spoja 10 u Spoj 6.
49. Postupak u skladu s patentnim zahtjevom 48, naznačen time što navedena kiselina je glioksilna kiselina.
50. Postupak u skladu s patentnim zahtjevom 48, naznačen time što korak prevođenja Spoja 10 u Spoj 6 se sastoji u reakciji Spoja 10 s malonskom kiselinom.
51. Postupak u skladu s patentnim zahtjevom 48, naznačen time što korak prevođenja Spoja 10 u Spoj 6 se sastoji u reakciji Spoja 10 s Wittigovim reagensom.
52. Postupak dobivanja Spoja 11:
[image]
naznačen time što se sastoji u:
(a) redukciji Spoja 17
[image]
kako bi se dobilo Spoj 20:
[image]
(b) prevođenju Spoja 20 u Spoj 14:
[image]
(c) prevođenju Spoja 14 u Spoj 15:
[image]
i
(d) prevođenju Spoja 15 u Spoj 11.
53. Postupak u skladu s patentnim zahtjevom 52, naznačen time što korak prevođenja Spoja 15 u Spoj 11 se sastoji u reakciji Spoja 15 sa Spojem 16:
[image]
kako bi se dobilo Spoj 11.
54. Postupak u skladu s patentnim zahtjevom 53, naznačen time što Spoj 16 se dobiva postupkom koji se sastoji u:
[image]
55. Postupak dobivanja Spoja 21:
[image]
naznačen time što se sastoji u ciklizaciji Spoja 22:
[image]
gdje X se bira iz skupine koju čine S, O i NH.
56. Postupak u skladu s patentnim zahtjevom 55, naznačen time što se provodi ciklizacija na povišenoj temperaturi, te se doda baza.
57. Postupak u skladu s patentnim zahtjevom 55, naznačen time što navedenu bazu se bira iz skupine koju čine organske, anorganske i organometalne baze.
58. Postupak u skladu s patentnim zahtjevom 57, naznačen time što navedenu bazu se bira iz skupine koju čine trietilamin; 1,5-diazabiciklo[4.3.0]non-5-en; 1,4-diazabiciklo[2.2.2]oktan; i 1,8-diazabiciklo[5.4.0]undec-7-en.
59. Postupak dobivanja Spoja 21, naznačen time što se sastoji u:
(a) prevođenju (R)-butinola u Spoj 23:
[image]
(b) reakciji Spoja 23 sa Spojem 6:
[image]
kako bi se dobilo Spoj 24:
[image]
(c) redukciji Spoja 24 u Spoj 22:
[image]
i
(d) ciklizaciji Spoja 22 kako bi se dobilo Spoj 21,
gdje X se bira iz skupine koju čine S, O i NH.
60. Postupak dobivanja Spoja 21:
[image]
naznačen time što se sastoji u:
(a) prevođenju (R)-butinola u Spoj 23:
[image]
(b) redukciji Spoja 23 kako bi se dobilo Spoj 25:
[image]
(c) reakciji Spoja 25 sa Spojem 6:
[image]
kako bi se dobilo Spoj 22:
[image]
i ciklizaciji Spoja 22 kako bi se dobilo Spoj 21,
gdje X se bira iz skupine koju čine S, O i NH.
61. Postupak u skladu s patentnim zahtjevom 60, naznačen time što Spoj 6 se dobiva postupkom koji se sastoji u:
(a) reakciji akroleina s CH3NO2 kako bi se dobilo Spoj 8:
[image]
(b) reakciji Spoja 8 s Na2S2O5 kako bi se dobilo Spoj 9:
[image]
(c) reakciji Spoja 9 s kiselinom kako bi se dobilo Spoj 10:
[image]
i
(d) prevođenju Spoja 10 u Spoj 6.
62. Postupak u skladu s patentnim zahtjevom 61, naznačen time što navedena kiselina je glioksilna kiselina.
63. Postupak u skladu s patentnim zahtjevom 61, naznačen time što korak prevođenja Spoja 10 u Spoj 6 se sastoji u reakciji Spoja 10 s malonskom kiselinom.
64. Postupak u skladu s patentnim zahtjevom 61, naznačen time što korak prevođenja Spoja 10 u Spoj 6 se sastoji u reakciji Spoja 10 s Wittigovim reagensom.
65. Postupak dobivanja Spoja 11:
[image]
naznačen time što se sastoji u:
(a) redukciji Spoja 21
[image]
kako bi se dobilo Spoj 26:
[image]
(b) prevođenju Spoja 26 u Spoj 27:
[image]
(c) prevođenju Spoja 27 u Spoj 14:
[image]
(d) prevođenju Spoja 14 u Spoj 15:
[image]
i
(e) prevođenju Spoja 15 u Spoj 11.
66. Postupak u skladu s patentnim zahtjevom 65, naznačen time što korak prevođenja Spoja 15 u Spoj 11 se sastoji u reakciji Spoja 15 sa Spojem 16:
[image]
kako bi se dobilo Spoj 11.
67. Postupak u skladu s patentnim zahtjevom 66, naznačen time što Spoj 16 se dobiva postupkom koji se sastoji u:
[image]
68. Postupak u skladu s patentnim zahtjevom 13, naznačen time što korak
[image]
je protočni korak, gdje Spojevi 3A i 3B se individualno nalaze u strujama reaktanata, gdje navedene struje se miješa ispred ulaza u pumpu, koja pumpa pomiješanu struju kroz statičnu miješalicu.
69. Postupak dobivanja Spoja 2:
[image]
gdje svakog od R5 i R6 se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne, heterocikličke i heteroarilne skupine, ili R5 i R6, zajedno s dušikom na kojeg su vezani, tvore 3- do 6-eročlani heterociklički spoj s 1 -4 heteroatoma, naznačen time što navedeni postupak se sastoji u:
(a) prevođenju (R)-butinola u Spoj 3:
[image]
(b) reakciji Spoja 3 sa Spojem 6 kako bi se dobilo Spoj 7:
[image]
i
(c) redukciji Spoja 7 kako bi se dobilo Spoj 2:
[image]
gdje:
"alkil" znači alifatska ugljikovodična skupina koja može biti nerazgranata ili razgranata i sadrži 1 do 24 atoma ugljika u lancu;
"alkenil" znači alifatska ugljikovodična skupina s nerazgranatim ili razgranatim lancem ugljika comprising jedan ili više dvostrukih veza u lancu, koje mogu biti konjugirane ili nekonjugirane, a osobito sadrži 2 do 15 atoma ugljika u lancu;
"alkinil" znači alifatska ugljikovodična skupina koja sadrži najmanje jednu trostruku vezu ugljik-ugljik i može biti nerazgranata ili razgranata i sadrži 2 do 15 atoma ugljika u lancu;
"alkoksi" znači alkil-O- skupina, u kojoj alkilna skupina je kao što je definirano gore, a osobito sadrži 1 do 12 atoma ugljika;
"cikloalkil" znači nesupstituirani ili supstituirani, zasićeni, stabilni, nearomatski, kemijski izvediv karbociklički prsten s, po mogućnosti, 3 do 15 atoma ugljika;
"heteroaril" znači monociklički ili policiklički aromatski prstenasti sustav s 5 do 14 atoma u prstenu, gdje jedan ili više atoma u prstenastom sustavu je/su atomi koji nisu ugljik.
70. Spoj, naznačen time što ima bilo koju od sljedećih formula:
[image]
gdje R1 se bira iz skupine koju čine OR2 i NR3R4, gdje svakog od R2, R3 i R4 se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne i heteroarilne skupine, gdje:
"alkil" znači alifatska ugljikovodična skupina koja može biti nerazgranata ili razgranata i sadrži 1 do 24 atoma ugljika u lancu;
"alkenil" znači alifatska ugljikovodična skupina s nerazgranatim ili razgranatim lancem ugljika comprising jedan ili više dvostrukih veza u lancu, koje mogu biti konjugirane ili nekonjugirane, a osobito sadrži 2 do 15 atoma ugljika u lancu;
"alkinil" znači alifatska ugljikovodična skupina koja sadrži najmanje jednu trostruku vezu ugljik-ugljik i može biti nerazgranata ili razgranata i sadrži 2 do 15 atoma ugljika u lancu;
"alkoksi" znači alkil-O- skupina, u kojoj alkilna skupina je kao što je definirano gore, a osobito sadrži 1 do 12 atoma ugljika;
"cikloalkil" znači nesupstituirani ili supstituirani, zasićeni, stabilni, nearomatski, kemijski izvediv karbociklički prsten s, po mogućnosti, 3 do 15 atoma ugljika;
"heteroaril" znači monociklički ili policiklički aromatski prstenasti sustav s 5 do 14 atoma u prstenu, gdje jedan ili više atoma u prstenastom sustavu je/su atomi koji nisu ugljik.
71. Spoj, naznačen time što ima bilo koju od sljedećih formula:
[image]
gdje R1 se bira iz skupine koju čine OR2 i NR3R4, gdje svakog od R2, R3 i R4 se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne i heteroarilne skupine, gdje:
"alkil" znači alifatska ugljikovodična skupina koja može biti nerazgranata ili razgranata i sadrži 1 do 24 atoma ugljika u lancu;
"alkenil" znači alifatska ugljikovodična skupina s nerazgranatim ili razgranatim lancem ugljika comprising jedan ili više dvostrukih veza u lancu, koje mogu biti konjugirane ili nekonjugirane, a osobito sadrži 2 do 15 atoma ugljika u lancu;
"alkinil" znači alifatska ugljikovodična skupina koja sadrži najmanje jednu trostruku vezu ugljik-ugljik i može biti nerazgranata ili razgranata i sadrži 2 do 15 atoma ugljika u lancu;
"alkoksi" znači alkil-O- skupina, u kojoj alkilna skupina je kao što je definirano gore, a osobito sadrži 1 do 12 atoma ugljika;
"cikloalkil" znači nesupstituirani ili supstituirani, zasićeni, stabilni, nearomatski, kemijski izvediv karbociklički prsten s, po mogućnosti, 3 do 15 atoma ugljika;
"heteroaril" znači monociklički ili policiklički aromatski prstenasti sustav s 5 do 14 atoma u prstenu, gdje jedan ili više atoma u prstenastom sustavu je/su atomi koji nisu ugljik.
72. Spoj, naznačen time što ima bilo koju od sljedećih formula:
[image]
gdje svakog od R5 i R6 se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne, heterocikličke i heteroarilne skupine, ili R5 i R6, zajedno s dušikom na kojeg su vezani, tvore 3- do 6-eročlani heterociklički spoj s 1-4 heteroatoma, te gdje R10 se bira između C1 do C10 alkilnih i arilnih skupina, gdje:
"alkil" znači alifatska ugljikovodična skupina koja može biti nerazgranata ili razgranata i sadrži 1 do 24 atoma ugljika u lancu;
"alkenil" znači alifatska ugljikovodična skupina s nerazgranatim ili razgranatim lancem ugljika comprising jedan ili više dvostrukih veza u lancu, koje mogu biti konjugirane ili nekonjugirane, a osobito sadrži 2 do 15 atoma ugljika u lancu;
"alkinil" znači alifatska ugljikovodična skupina koja sadrži najmanje jednu trostruku vezu ugljik-ugljik i može biti nerazgranata ili razgranata i sadrži 2 do 15 atoma ugljika u lancu;
"alkoksi" znači alkil-O- skupina, u kojoj alkilna skupina je kao što je definirano gore, a osobito sadrži 1 do 12 atoma ugljika;
"cikloalkil" znači nesupstituirani ili supstituirani, zasićeni, stabilni, nearomatski, kemijski izvediv karbociklički prsten s, po mogućnosti, 3 do 15 atoma ugljika;
"heteroaril" znači monociklički ili policiklički aromatski prstenasti sustav s 5 do 14 atoma u prstenu, gdje jedan ili više atoma u prstenastom sustavu je/su atomi koji nisu ugljik.
73. Spoj, naznačen time što ima bilo koju od sljedećih formula:
[image]
gdje svakog od R5 i R6 se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne, heterocikličke i heteroarilne skupine, ili R5 i R6, zajedno s dušikom na kojeg su vezani, tvore 3- do 6-eročlani heterociklički spoj s 1-4 heteroatoma, gdje:
"alkil" znači alifatska ugljikovodična skupina koja može biti nerazgranata ili razgranata i sadrži 1 do 24 atoma ugljika u lancu;
"alkenil" znači alifatska ugljikovodična skupina s nerazgranatim ili razgranatim lancem ugljika comprising jedan ili više dvostrukih veza u lancu, koje mogu biti konjugirane ili nekonjugirane, a osobito sadrži 2 do 15 atoma ugljika u lancu;
"alkinil" znači alifatska ugljikovodična skupina koja sadrži najmanje jednu trostruku vezu ugljik-ugljik i može biti nerazgranata ili razgranata i sadrži 2 do 15 atoma ugljika u lancu;
"alkoksi" znači alkil-O- skupina, u kojoj alkilna skupina je kao što je definirano gore, a osobito sadrži 1 do 12 atoma ugljika;
"cikloalkil" znači nesupstituirani ili supstituirani, zasićeni, stabilni, nearomatski, kemijski izvediv karbociklički prsten s, po mogućnosti, 3 do 15 atoma ugljika;
"heteroaril" znači monociklički ili policiklički aromatski prstenasti sustav s 5 do 14 atoma u prstenu, gdje jedan ili više atoma u prstenastom sustavu je/su atomi koji nisu ugljik.
74. Spoj, naznačen time što ga se bira iz skupine koju čine:
[image]
gdje X je definiran kao u patentnom zahtjevu 55, a R7 je definiran kao u patentnom zahtjevu 36.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64446405P | 2005-01-14 | 2005-01-14 | |
PCT/US2006/000954 WO2006076415A2 (en) | 2005-01-14 | 2006-01-12 | Exo- and diastereo- selective syntheses of himbacine analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100218T1 true HRP20100218T1 (hr) | 2010-05-31 |
Family
ID=36168544
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100218T HRP20100218T1 (hr) | 2005-01-14 | 2010-04-16 | Egzo- i dijastereoselektivna sinteza analoga himbacina |
HR20110963T HRP20110963T1 (hr) | 2005-01-14 | 2011-12-21 | Egzo- i diastereo-selektivne sinteze analoga himbacina |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110963T HRP20110963T1 (hr) | 2005-01-14 | 2011-12-21 | Egzo- i diastereo-selektivne sinteze analoga himbacina |
Country Status (22)
Country | Link |
---|---|
US (4) | US7605275B2 (hr) |
EP (4) | EP1848705B1 (hr) |
JP (3) | JP4681616B2 (hr) |
CN (2) | CN102757423B (hr) |
AR (1) | AR056919A1 (hr) |
AT (2) | ATE458726T1 (hr) |
CA (2) | CA2875768C (hr) |
CY (2) | CY1109896T1 (hr) |
DE (1) | DE602006012450D1 (hr) |
DK (2) | DK1848705T3 (hr) |
ES (3) | ES2412981T3 (hr) |
HK (1) | HK1108893A1 (hr) |
HR (2) | HRP20100218T1 (hr) |
ME (1) | ME01967B (hr) |
MX (1) | MX2007008665A (hr) |
PL (2) | PL2206697T3 (hr) |
PT (2) | PT1848705E (hr) |
RS (2) | RS51315B (hr) |
SG (2) | SG192505A1 (hr) |
SI (2) | SI2206697T1 (hr) |
WO (1) | WO2006076415A2 (hr) |
ZA (1) | ZA200706711B (hr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
EP1853592B1 (en) * | 2005-01-14 | 2011-03-02 | Schering Corporation | Synthesis of himbacine analogs |
US7772276B2 (en) | 2005-01-14 | 2010-08-10 | Schering Corporation | Exo-selective synthesis of himbacine analogs |
PT1848705E (pt) | 2005-01-14 | 2010-05-10 | Schering Corp | Sínteses exo- e diastereo-selectivas de análogos da himbacina |
CN101384259A (zh) * | 2005-12-22 | 2009-03-11 | 先灵公司 | 作为预防来自心肺外科手术的并发症的凝血酶受体拮抗剂 |
AR061727A1 (es) * | 2006-06-30 | 2008-09-17 | Schering Corp | Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato |
JP5099563B2 (ja) * | 2006-06-30 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | 3−(5−ニトロシクロヘキサ−1−エニル)アクリル酸およびそのエステルの合成 |
CN101610999A (zh) * | 2006-12-15 | 2009-12-23 | 先灵公司 | α-酮酰胺的亚硫酸氢盐纯化方法 |
JP5668476B2 (ja) | 2007-10-08 | 2015-02-12 | オーリニア・ファーマシューティカルズ・インコーポレイテッドAurinia Pharmaceuticals Inc. | カルシニューリン阻害剤またはmTOR阻害剤を含む眼科用組成物 |
CA2703487A1 (en) * | 2007-10-24 | 2009-04-30 | Schering Corporation | High purity synthetic process for the preparation of dodecahydro-naptho-furanyl-carbamic acid ester intermediates |
EP2723816A1 (fr) * | 2011-06-21 | 2014-04-30 | Bluestar Silicones France | Inhibiteurs de reaction d'hydrosilylation, et leur application pour la preparation de compositions silicones durcissables stables. |
CN105330689B (zh) * | 2014-08-08 | 2018-08-17 | 博瑞生物医药(苏州)股份有限公司 | 制备Himbacine类似物中间体的制备方法 |
CN105985303B (zh) * | 2015-02-13 | 2020-08-14 | 上海彩迩文生化科技有限公司 | 抗凝血剂的制备方法、中间体及其制备方法 |
CN105348241B (zh) * | 2015-12-11 | 2017-09-05 | 南京华威医药科技开发有限公司 | 一种硫酸沃拉帕沙中间体的合成方法 |
US11247940B2 (en) | 2016-10-26 | 2022-02-15 | The Regents Of The University Of California | Efficient integration of manufacturing of upcycled concrete product into power plants |
CN106749138B (zh) * | 2016-12-07 | 2019-08-16 | 扬子江药业集团四川海蓉药业有限公司 | 一种硫酸沃拉帕沙中间体醛的制备方法 |
CN106866450B (zh) * | 2017-01-13 | 2019-01-11 | 阜阳欣奕华材料科技有限公司 | 硫酸沃拉帕沙中间体的制备方法 |
CN108658910B (zh) * | 2017-03-29 | 2020-11-03 | 北京新领先医药科技发展有限公司 | 一种沃拉帕沙中间体1-α的制备方法 |
US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
WO2019006352A1 (en) | 2017-06-30 | 2019-01-03 | The Regents Of The University Of California | CO2 MINERALIZATION IN PRODUTED AND INDUSTRIAL EFFLUENT WATER BY PH CHANGE CARBONATION |
EP3668820A4 (en) | 2017-08-14 | 2021-05-05 | The Regents of the University of California, A California Corporation | REDUCING THE ALKALINE-SILICA REACTION IN CONCRETE USING SLIGHTLY SOLUBLE CHEMICAL ADDITIVES |
WO2019057946A1 (en) | 2017-09-25 | 2019-03-28 | F. Hoffmann-La Roche Ag | MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS |
US11384029B2 (en) | 2019-03-18 | 2022-07-12 | The Regents Of The University Of California | Formulations and processing of cementitious components to meet target strength and CO2 uptake criteria |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9810685B (en) * | 1997-11-25 | 1999-12-23 | Schering Corp | Thrombin receptor antagonists. |
US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
ATE267209T1 (de) * | 1998-05-05 | 2004-06-15 | Lilly Co Eli | Reinigung von carboxaldehyd |
US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
US20040192753A1 (en) | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
US7235567B2 (en) | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
US6645987B2 (en) | 2000-06-15 | 2003-11-11 | Schering Corporation | Nor-seco himbacine derivatives useful as thrombin receptor antagonists |
US8124625B2 (en) * | 2001-09-14 | 2012-02-28 | Shionogi & Co., Ltd. | Method of enhancing the expression of apolipoprotein AI using olefin derivatives |
MY139335A (en) * | 2001-10-18 | 2009-09-30 | Schering Corp | Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists |
PT1495018E (pt) * | 2002-04-16 | 2008-02-19 | Schering Corp | Antagonistas tricíclicos de receptores de trombina |
CA2567981C (en) * | 2004-05-28 | 2010-08-31 | Schering Corporation | Constrained himbacine analogs as thrombin receptor antagonists |
US7772276B2 (en) * | 2005-01-14 | 2010-08-10 | Schering Corporation | Exo-selective synthesis of himbacine analogs |
PT1848705E (pt) | 2005-01-14 | 2010-05-10 | Schering Corp | Sínteses exo- e diastereo-selectivas de análogos da himbacina |
US7541471B2 (en) * | 2005-01-14 | 2009-06-02 | Schering Corporation | Synthesis of himbacine analogs |
EP1853592B1 (en) * | 2005-01-14 | 2011-03-02 | Schering Corporation | Synthesis of himbacine analogs |
-
2006
- 2006-01-12 PT PT06718069T patent/PT1848705E/pt unknown
- 2006-01-12 AT AT06718069T patent/ATE458726T1/de active
- 2006-01-12 CA CA2875768A patent/CA2875768C/en active Active
- 2006-01-12 RS RSP-2010/0221A patent/RS51315B/sr unknown
- 2006-01-12 AT AT10001844T patent/ATE530516T1/de active
- 2006-01-12 EP EP06718069A patent/EP1848705B1/en active Active
- 2006-01-12 PL PL10001844T patent/PL2206697T3/pl unknown
- 2006-01-12 ES ES10001846T patent/ES2412981T3/es active Active
- 2006-01-12 RS RS20110567A patent/RS52117B/en unknown
- 2006-01-12 ES ES10001844T patent/ES2374379T3/es active Active
- 2006-01-12 DK DK06718069.5T patent/DK1848705T3/da active
- 2006-01-12 AR ARP060100127A patent/AR056919A1/es not_active Application Discontinuation
- 2006-01-12 DE DE602006012450T patent/DE602006012450D1/de active Active
- 2006-01-12 SI SI200631234T patent/SI2206697T1/sl unknown
- 2006-01-12 DK DK10001844.9T patent/DK2206697T3/da active
- 2006-01-12 ES ES06718069T patent/ES2339696T3/es active Active
- 2006-01-12 US US11/331,324 patent/US7605275B2/en active Active
- 2006-01-12 SI SI200630633T patent/SI1848705T1/sl unknown
- 2006-01-12 CN CN201210217378.8A patent/CN102757423B/zh not_active Expired - Fee Related
- 2006-01-12 EP EP10001844A patent/EP2206697B1/en active Active
- 2006-01-12 JP JP2007551342A patent/JP4681616B2/ja not_active Expired - Fee Related
- 2006-01-12 CA CA2594871A patent/CA2594871C/en active Active
- 2006-01-12 SG SG2013053558A patent/SG192505A1/en unknown
- 2006-01-12 PT PT10001844T patent/PT2206697E/pt unknown
- 2006-01-12 PL PL06718069T patent/PL1848705T3/pl unknown
- 2006-01-12 WO PCT/US2006/000954 patent/WO2006076415A2/en active Application Filing
- 2006-01-12 EP EP10001845.6A patent/EP2196454B1/en active Active
- 2006-01-12 ME MEP-2011-567A patent/ME01967B/me unknown
- 2006-01-12 EP EP10001846.4A patent/EP2196468B1/en active Active
- 2006-01-12 CN CN2006800080103A patent/CN101193880B/zh not_active Expired - Fee Related
- 2006-01-12 SG SG201000281-4A patent/SG158888A1/en unknown
- 2006-01-12 MX MX2007008665A patent/MX2007008665A/es active IP Right Grant
-
2007
- 2007-08-13 ZA ZA2007/06711A patent/ZA200706711B/en unknown
-
2008
- 2008-03-13 HK HK08102973.9A patent/HK1108893A1/xx not_active IP Right Cessation
-
2009
- 2009-07-17 US US12/505,079 patent/US7989653B2/en active Active
-
2010
- 2010-03-16 CY CY20101100243T patent/CY1109896T1/el unknown
- 2010-04-16 HR HR20100218T patent/HRP20100218T1/hr unknown
- 2010-12-09 JP JP2010275167A patent/JP5388231B2/ja not_active Expired - Fee Related
-
2011
- 2011-06-24 US US13/168,029 patent/US8258319B2/en active Active
- 2011-12-21 HR HR20110963T patent/HRP20110963T1/hr unknown
-
2012
- 2012-01-24 CY CY20121100078T patent/CY1112371T1/el unknown
- 2012-07-31 US US13/563,136 patent/US8618314B2/en active Active
-
2013
- 2013-04-26 JP JP2013093811A patent/JP5911447B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100218T1 (hr) | Egzo- i dijastereoselektivna sinteza analoga himbacina | |
CA2731800C (en) | Processes and intermediates for making sweet taste enhancers | |
Hegedus et al. | Palladium-assisted carboacylation of olefins | |
KR870000210B1 (ko) | 로듐촉매의 제조방법 | |
EP3486248B1 (en) | Improved methods for the acylation of maytansinol | |
ES2592727T3 (es) | Nuevo proceso para la preparación de derivados del ácido ciclohexanocarboxílico | |
EP1669346A1 (de) | Verfahren zur Herstellung von Carbaminsäureester-Derivaten | |
Saito et al. | Structures of norsecurinine and dihydronorsecurinine | |
Strazzolini et al. | Oxiranes from methylenation of the ester carbonyl group by diazomethane | |
Jia et al. | Reductive Cleavage of SS Bond by Samarium Diiodide: A Novel Method for the Synthesis of Disulfides | |
Skell et al. | Relaxation of excited state carbene to ground state. Internal heavy atom effect | |
UA78511C2 (en) | A process for the preparation of cyclohexanol derivatives | |
CN102803193A (zh) | 降冰片烯衍生物的制造方法 | |
KR101162160B1 (ko) | 산 무수물 및/또는 산 할로겐화물 및 삼산화 황으로부터입체 장애 2급 아미노에터 알콜을 합성하는 방법 | |
CN110878025A (zh) | 一种芳香类硝基化合物还原成芳香胺类化合物的方法 | |
Shaw et al. | Np-Toluenesulfinylimidazole: A New in situ Reagent for the Mild and Efficient Synthesis of p-Toluenesulfinate Alkyl Esters and Aryl Esters | |
EP1086941B1 (en) | Process for preparing reductants of unsaturated organic compounds by the use of trichlorosilane and reducing agents | |
Hossain et al. | Rearrangements in the Reduction of 3-Iodobicyclo [1.1. 1] pentyl Azide with Lithium Aluminum Hydride: Mechanistic Evidence of Intermediates | |
US20200140358A1 (en) | Process for the production of semifluorinated alkanes | |
CA1213910A (en) | Process for producing aminobenzylamines | |
Polley et al. | Synthesis of 1, 3-bishomoadamantane | |
CN100556906C (zh) | 一种蛋白酶抑制剂重要中间体的制备方法 | |
Murray et al. | Polycyclic azetidines. I. The preparation of benzo [c]‐cis‐6‐azabicyclo [3.2. 0] heptane | |
BRPI0716247A2 (pt) | processo para preparar de derivados de n-metiladamantil por uma reaÇço de ligaÇço catalisada por palÁdio seguida por aminaÇço redutiva | |
Lai et al. | A One-Pot and Efficient Preparation of (S)-Benzyl 4-Hydroxy-2-Pentynoate from (S)-n-Butyn-2-Ol Using an Unusual Lithiation with n-BuLi and a Catalytic Amount of Hexamethyldisilazane |